That which distinguishes man from the animal kingdom is the imago Dei, the image of God. The image of God has traditionally been identified with such things as rationality, self-consciousness, the exercise of dominion, and moral conscience. However, we must be careful in defining the image of God in wholly functional terms. The image of God is as much a state as it is a capacity. The image is not to be conceived as an end in a process whereby an unborn entity progresses into personhood. The image is a given, not a goal to which the fetus moves in its physiological development. No one denies that the fetus develops. But this development is not from non-person to part-person to full-person, but rather from full-person to the consummate expression and experience of all that personhood entails.
Sam Storms

Obsessive Compulsive Disorder

Obsessive Compulsive Disorder Chaney DS, et al. Serotonergic function in obsessive compulsive disorder. Arch Gen Psychiatry 1988; 45: 177-185. Flament MF, Rapoport JL, et al. Biochemical changes during clomipramine treatment of childhood obsessive-compulsive disorder. Arch Gen Psychiatry 1987; 44:219-225. Fontaine R, Chouinard G. An open trial of fluoxetine in the treatment of obsessive compulsive disorder. J Clin Psychopharmacol 1986; 6: 98- 101. Fontaine R, Chouinard G. Fluoxetine in the long term maintenance treatment of obsessive compulsive disorder. Psychiatric Annals 1989; 19: 88- 91. Fyer AJ, Mannuzza S, Endicott J. Differential diagnosis and assessment of anxiety: recent developments, in Meltzer HY (ed.): Psychopharmacology: the third generation of progress, pp. 1177-1191. New York: Raven Press, 1987. Goodwin D, Guse S, et al. Follow-up studies in obsessional neurosis. Arch Gen Psych 1963; 20: 182-7. Hollander E, De Caria C, et al. Biological aspects of obsessive compulsive disorder. Psychiatric Annals 1989; 19: 80-87. Hollander E, Fay M, et al. Serotonergic and noradrenergic sensitivity in OCD: behavioral findings. Am J Psychiatry 1988; 145: 1015-17. Insel TR, Gillin JC, et al. Sleep in obsessive compulsive disorder. Arch Gen Psychiatry 1982; 39: 1372-1377. Insel TR, Kaslin NH, et al. The DST in patients with primary obsessive compulsive disorder. Psychiatry Res 1983; 6: 153-158. Insel TR, Murphy DL, et al. Obsessive compulsive disorder. A double- blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983; 40: 605-612. Insel TR, Murphy DL. The psychopharmacologic treatment of obsessive- compulsive disorder: a review. J Clin Psychopharm 1981; 1: 304-311. Insel TR, Zahn T, Murphy DL. In Tuma AH, Maser JD (eds): Anxiety and the anxiety disorders, pp.577-590. Hillsdale, NJ: Lawrence Earlbaum Associates, 1985. Insel TR, Zohar J. Psychopharmacologic approaches to obsessive compulsive disorder, in Meltzer HY (ed.): Psychopharmacology: the third generation of progress, pp. 1205-1210. New York: Raven Press, 1987. Jenike MA, Baer L. An open trial of buspirone in OCD. Am J Psychiatry 1988; 145: 1285-1286. Lewis A. Problems of obsessional illness. Proc R Soc Med 1935; 29:325-336. Perse TL, Greist JH, et al. Fluvoxamine treatment of OCD. Am J Psychiatry 1987; 144: 1543-48. Price LH, Goodman WK, Charney DS, et al. Treatment of severe OCD with fluvoxamine. Am J Psychiatry 1987; 144:1059-61. Rachman S, Hodgson R. Obsessions and Compulsions. Englewood Cliffs, NJ: Prentice Hall, 1980. Rasmussen SA, Eisen JL. Clinical features and phenomenology of obsessive compulsive disorder. Psychiatric Annals 1989;19: 67-73. Robins LN, Helzer JE, et al. Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 1984; 41: 949-959. Salzman L. The treatment of the obsessive compulsive personality. New York: Jason Aronson, 1980. Schatzberg AF, Dessain, E, et al. Recent Studies on selective serotonergic antidepressants: trazodone, fluoxetine, and fluvoxamine. J Clin Psychopharmacol 1987; 7: 44S-49S. Seiver L, Insel TR, et al. Blunted growth hormone response to clonidine in obsessive compulsive disorder. Br J Psychiatry 1983; 142: 184- 188. Tan E, Marks I, Marset P. Bimedial leucotomy in obsessive compulsive neurosis: a controlled serial inquiry. Br J Psychiatry 1971; 118: 155-64. Thoren P, Asberg M, et al. Clomipramine treatment of obsessive disorder: biochemical and clinical aspects. Arch Gen Psychiatry 1980; 37: 1289-1294. Turner SM, Jacob RG, et al. Fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacology 1985; 5: 207-212. Zak JP, Miller JA, et al. The potential role of serotonin reuptake inhibitors in the treatment of obsessive compulsive disorder. J Clin Psychiatry 1988; 49: 23S-29S. Zohar J, Insel, TR, et al. Serotonergic responsivity in OCD. Effects of Chronic Clomipramine treatment. Arch Gen Psychiatry 1988; 45:167- 172. Zohar J, Insel TR. Obsessive-compulsive disorder:psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987; 22: 667-687. Zohar J, Mueller EA, Insel TR, et al. Serotonergic Responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry 1987; 44:946-951.